Sector News

Merck buys out IOmet, adding new immuno-oncology tech

January 12, 2016
Life sciences

Merck has snagged Edinburgh-based IOmet for an undisclosed sum, adding a preclinical pipeline of therapies that target the IDO/TDO pathways that may help spur an immune system attack on cancer.

A leader in the checkpoint inhibition field with the pioneering Keytruda, Merck is gaining access to technology that promises to target enzymes that are often overexpressed in cancers, leading to tryptophan depletion and high tumor levels of the breakdown product, kynurenine, an imbalance that tamps down the immune response.

As a result, IDO/TDO are two pathways that have attracted considerable attention from pharma companies zeroing in on immunotherapy. Roche struck a deal with India’s Curadev last April, paying $25 million up front and offering $530 million in milestones for access to its IDO/TDO work. Roche is considered just one step behind Merck and Bristol-Myers Squibb ($BMY) with the PD-L1 checkpoint program for atezolizumab.

Incyte has already paired with Merck’s Keytruda–and other checkpoints–on its IDO1 drug epacadostat (INCB24360).

“The acquisition of IOmet is a further example of Merck’s commitment to fully realizing the potential of this rapidly evolving field through our existing innovative portfolio as well as the acquisition of promising immunotherapeutic candidates,” said Dr. Eric Rubin, vice president and therapeutic area head of oncology early-stage development at Merck Research Laboratories.

By John Carroll

Source: Fierce Biotech

Related News

February 21, 2021

Sanofi invests in health tech firm Novadiscovery, boosting trial simulation platform and COVID-19 work

Life sciences

Novadiscovery uses its so-called JINKO platform that runs disease models on virtual patients to support decision-making and de-risk clinical development.

February 21, 2021

Gilead lets local HIV community groups take the lead with $3M grant

Life sciences

The pharma is pledging $3.2 million over two years to the Human Rights Campaign, the largest lesbian, gay, bisexual, transgender and queer (LGBTQ+) civil rights organization in the U.S.

February 21, 2021

Biotech company funds research project on diversity

Life sciences

In collaboration with Genmab, a new anthropological postdoc project at the Department of Anthropology will now explore and help develop the company’s efforts to ensure a diverse and inclusive workplace.

Send this to a friend